HIV and drug hypersensitivity

Drug Hypersensitivity

Volumn , Issue , 2007, Pages 84-94

  Pirmohamed Prof , Munir ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861428472     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000104192     Document Type: Chapter

References (86)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immuno-deficiency virus infection. HIV Outpa-tient Study Investigators. N Engl J Med 1998;338:853-860.
2. Carr A, Cooper DA: Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-1430.
3. Carr A, Cooper DA: Pathogenesis and management of HIV-associated drug hypersensitivity. AIDS Clin Rev 1995;96:65-97.
4. Pirmohamed M, Park BK: Drug reactions in HIV infected patients. Post-grad Doctor 1995;18:438-444.
5. Pirmohamed M, Park BK: HIV and drug allergy. Curr Opin Allergy Clin Immunol 2001;1:311-316.
6. Coopman SA, Johnson RA, Platt R, Stern RS: Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993;328:1670-1674.
7. Roujeau JC, Stern RS: Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-1285.
8. Escaut L, Liotier JY, Albengres E, Cheminot N, Vittecoq D: Abacavir re-challenge has to be avoided in case of hypersensitivity reaction. AIDS 1999;13:1419-1420.
9. Rich JD, Sullivan T, Greineder D, Kazanjian PH: Trimethoprim/sulfa-methoxazole incremental dose regimen in human immunodeficiency virus-infected persons. Ann Allergy Asthma Immunol 1997;79:409-414.
10. Fagot JP, Mockenhaupt M, Bouwes Bavinck JN, Naldi L, Viboud C, Roujeau JC: Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001;15:1843-1848.
11. Abrescia N, D'Abbraccio M, Figoni M, Busto A, Maddaloni A, De Marco M: Hepatotoxicity of antiretroviral drugs. Curr Pharm Des 2005;11:3697-3710.
12. Martinez E, Blanco JL, Arnaiz JA, Perez Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, Garcia Viejo MA, Mallolas J, Carne X, Phillips A, Gatell JM: Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001;15:1261-1268.
13. Crabb C: GlaxoSmithKline ends aplavi-roc trials. AIDS 2006;20:641.
14. Lopez Bernaldo de Quiros JC, Miro JM, Pena JM, Podzamczer D, Alberdi JC, Martinez E, Cosin J, Claramonte X, Gonzalez J, Domingo P, Casado JL, Ri-bera E: A randomized trial of the dis-continuation of primary and secondary prophylaxis against Pneumocystis ca-rinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med 2001;344:159-167.
15. Ledergerber B, Mocroft A, Reiss P, Fur-rer H, Kirk O, Bickel M, Uberti Foppa C, Pradier C, D'Arminio Monforte A, Schneider MM, Lundgren JD: Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med 2001;344:168-174.
16. van der Ven AJ, Koopmans PP, Vree TB, van der Meer JW: Adverse reactions to co-trimoxazole in HIV infection. Lan-cet 1991;ii:431-433.
17. Cribb AE, Lee BL, Trepanier LA, Spiel-berg SP: Adverse reactions to sulphon-amide and sulphonamide-tri-methoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug React Toxicol Rev 1996;15:9-50.
18. Schnyder B, Mauri-Hellweg D, Zanni M, Bettens F, Pichler WJ: Direct, MHC-dependent presentation of the drug sulfamethoxazole to human α/β T cell clones. J Clin Invest 1997;100:136-141.
19. Schnyder B, Burkhart C, Schnyder-Frutig K, von Greyerz S, Naisbitt DJ, Pirmohamed M, Park BK, Pichler WJ: Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individu-als. J Immunol 2000;164:6647-6654.
20. Schmid DA, Depta JP, Luthi M, Pichler WJ: Transfection of drug-specific T-cell receptors into hybridoma cells: tools to monitor drug interaction with T-cell receptors and evaluate cross-reactivity to related compounds. Mol Pharmacol 2006;70:356-365.
21. Park BK, Naisbitt DJ, Gordon SF, Kitteringham NR, Pirmohamed M: Meta-bolic activation in drug allergies. Toxi-cology 2001;158:11-23.
22. Naisbitt DJ, Gordon SF, Pirmohamed M, Park BK: Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf 2000;23:483-507.
23. Cribb AE, Spielberg SP, Griffin GP: N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab Dispos 1995;23:406-414.
24. van der Ven AJ, Vree TB, van Ewijk-Beneken Kolmer EW, Koopmans PP, van der Meer JW: Urinary recovery and kinetics of sulphamethoxazole and its metabolites in HIV-seropositive patients and healthy volunteers after a single oral dose of sulphamethoxazole. Br J Clin Pharmacol 1995; 39: 621-625.
25. Reilly TP, Lash LH, Doll MA, Hein DW, Woster PM, Svensson CK: A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J Invest Dermatol 2000; 114: 1164-1173.
26. Baron JM, Holler D, Schiffer R, Frankenberg S, Neis M, Merk HF, Jugert FK: Expression of multiple cytochrome p450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes. J Invest Dermatol 2001; 116: 541-548.
27. Roychowdhury S, Vyas PM, Reilly TP, Gaspari AA, Svensson CK: Characterization of the formation and localization of sulfamethoxazole and dapsone associated drug-protein adducts in human epidermal keratinocytes. J Pharmacol Exp Ther 2005; 314: 43-52.
28. Bhaiya P, Roychowdhury S, Vyas PM, Doll MA, Hein DW, Svensson CK: Bioactivation, protein haptenation, and toxicity of sulfamethoxazole and dapsone in normal human dermal fibroblasts. Toxicol Appl Pharmacol 2006; 215: 158-167.
29. Naisbitt DJ, Hough SJ, Gill HJ, Pirmohamed M, Kitteringham NR, Park BK: Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity. Br J Pharmacol 1999; 126: 1393-1407.
30. Hertl M, Jugert F, Merk HF: CD8(+) dermal T-cells from a sulfamethoxazole-induced bullous exanthem proliferate in response to drug-modified liver-microsomes. Br J Dermatol 1995; 132: 215-220
31. Farrell J, Naisbitt DJ, Drummond NS, Depta JPH, Vilar FJ, Pirmohamed M, Park BK: Characterization of sulfa-methoxazole and sulfamethoxazole metabolite-specific T-cell responses in animals and humans. J Pharmacol Exp Ther 2003; 306: 229-237.
32. Rieder MJ, Uetrecht JP, Shear NH, Cannon M, Miller M, Spielberg SP: Diagnosis of sulfonamide hypersensitivity reactions by in-vitro 'rechallenge' with hydroxylamine metabolites. Ann In-tern Med 1989; 110: 286-289.
33. Carr A, Tindall B, Penny R, Cooper DA: In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV. Clin Exp Immunol 1993; 94: 21-25.
34. Reilly TP, MacArthur RD, Farrough MJ, Crane LR, Woster PM, Svensson CK: Is hydroxylamine-induced cyto-toxicity a valid marker for hypersensitivity reactions to sulfamethoxazole in human immunodeficiency virus-in-fected individuals? J Pharmacol Exp Ther 1999; 291: 1356-1364.
35. Arp J, Rieder MJ, Urquhart B, Freeman D, Tucker MJ, Krizova A, Lehmann D, Dekaban GA: Hypersensitivity of HIV-1-infected cells to reactive sulfonamide metabolites correlated to expression of the HIV-1 viral protein tat. J Pharmacol Exp Ther 2005; 314: 1218-1225.
36. Choi J, Liu RM, Kundu RK, Sangiorgi F, Wu W, Maxson R, Forman HJ: Molecular mechanism of decreased glutathi-one content in human immunodeficiency virus type 1 tat-transgenic mice. J Biol Chem 2000; 275: 3693-3698.
37. Burkhart C, von Greyerz S, Depta JP, Naisbitt DJ, Britschgi M, Park KB, Pichler WJ: Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfa-methoxazole-metabolite-specific hu-man CD4+ T-cells. Br J Pharmacol 2001; 132: 623-630.
38. Naisbitt DJ, O'Neill PM, Pirmohamed M, Park BK: Synthesis and reactions of nitroso sulfamethoxazole with biologi-cal nucleophiles-implications for immune-mediated toxicity. Bioorg Med Chem Lett 1996; 6: 1511-1516.
39. Aukrust P, Svardal AM, Muller F, Lunden B, Berge RK, Ueland PM, Froland SS: Increased levels of oxidized glutathione in CD4+ lymphocytes associated with disturbed intracellular redox balance in human immunodeficiency virus type 1 infection. Blood 1995; 86: 258-267.
40. Naisbitt DJ, Vilar J, Stalford A, Wilkins EGL, Pirmohamed M, Park BK: Plasma cysteine and decreased reduction of nitroso sulphamethoxazole with HIV infection. AIDS Res Hum Retrov 2000; 16: 1929-1938.
41. Trepanier LA, Yoder AR, Bajad S, Beck-with MD, Bellehumeur JL, Graziano FM: Plasma ascorbate deficiency is as-sociated with impaired reduction of sulfamethoxazole-nitroso in HIV infection. J Acquir Immune Defic Syndr 2004; 36: 1041-1050.
42. Lavergne SN, Kurian JR, Bajad SU, Maki JE, Yoder AR, Guzinski MV, Graziano FM, Trepanier LA: Roles of en-dogenous ascorbate and glutathione in the cellular reduction and cytotoxicity of sulfamethoxazole-nitroso. Toxicology 2006; 222: 25-36.
43. Zielinska E, Niewiarowski W, Bodalski J, Rebowski G, Skretkowicz J, Mianowska K, Sekulska M: Genotyping of the arylamine N-acetyltransferase polymorphism in the prediction of idiosyn-cratic reactions to trimethoprim-sulfa-methoxazole in infants. Pharm World Sci 1998; 20: 123-130.
44. Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP: Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991; 49: 13-17.
45. Wolkenstein P, Carriere V, Charue D, Bastujigarin S, Revuz J, Roujeau JC, Beaune P, Bagot M: A slow acetylator genotype is a risk factor for sulfon-amide-induced toxic epidermal necrol-ysis and Stevens-Johnson syndrome. Pharmacogenetics 1995; 5: 255-258.
46. Pirmohamed M, Alfirevic A, Vilar J, Stalford A, Wilkins EGL, Sim E, Park BK: Association analysis of drug me-tabolizing enzyme gene polymorphisms in HIV-positive patients with cotrimoxazole hypersensitivity. Pharmacogenetics 2000; 10: 705-713.
47. Pirmohamed M: Genetic factors in the predisposition to drug-induced hyper-sensitivity reactions. AAPS J 2006; 8:E20-E26.
48. Matzinger P: Tolerance, danger, and the extended family. Annu Rev Immu-nol 1994; 12: 991-1045.
49. Pantaleo G, Fauci AS: New concepts in the immunopathogenesis of HIV infection. Annu Rev Immunol 1995; 13: 487-512.
50. Baier-Bitterlich G, Fuchs D, Wachter H: Chronic immune stimulation, oxidative stress, and apoptosis in HIV infection. Biochem Pharmacol 1997; 53:755-763.
51. Schnyder B, Frutig K, Mauri-Hellweg D, Limat A, Yawalkar N, Pichler WJ: T-cell-mediated cytotoxicity against ke-ratinocytes in sulfamethoxazol-in-duced skin reaction. Clin Exp Allergy 1998; 28: 1412-1417.
52. Rieder MJ, Krause R, Bird IA, Dekaban GA: Toxicity of sulfonamide-reactive metabolites in HIV-infected, HTLV-infected, and noninfected cells. J Ac-quir Immune Defic Syndr Hum Retro-virol 1995; 8: 134-140.
53. Sullivan JR, Shear NH: The drug hyper-sensitivity syndrome: what is the pathogenesis? Arch Dermatol 2001; 137: 357-364.
54. Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, Lafon S, Pearce G, Steel H: Hypersensitivity reactions during therapy with the nu-cleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23: 1603-1614.
55. Clay PG, Rathbun RC, Slater LN: Management protocol for abacavir-related hypersensitivity reaction. Ann Phar-macother 2000; 34: 247-249.
56. Walsh JS, Reese MJ, Thurmond LM: The metabolic activation of abacavir by human liver cytosol and expressed hu-man alcohol dehydrogenase isozymes. Chem Biol Interact 2002; 142: 135-154.
57. Dodd CC, Naisbitt DJ, Vilar FJ, Gordon SF, Maggs JL, Park BK, Pirmohamed M: Abacavir hypersensitivity in human immunodeficiency virus-positive patients: demonstration of the presence of drug-specific lymphocyte proliferation in vitro. Br J Clin Pharmacol 2003; 55: 421-421.
58. Phillips EJ, Wong GA, Kaul R, Shahabi K, Nolan DA, Knowles SR, Martin AM, Mallal SA, Shear NH: Clinical and im-munogenetic correlates of abacavir hy-persensitivity. AIDS 2005; 19: 979-981.
59. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT: Association between presence of HLA-B * 5701, HLA-DR7 , and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet 2002; 359: 727-732.
60. Martin AM, Nolan D, Gaudieri S, Al-meida CA, Nolan R, James I, Carvalho F, Phillips E, Christiansen FT, Purcell AW, McCluskey J, Mallal S: Predisposition to abacavir hypersensitivity conferred by HLA-B * 5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 2004; 101: 4180-4185.
61. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, Davies K, Handley A, Dow DJ, Fling ME, Stocum M, Bowman C, Thurmond LM, Roses AD: Genetic variations in HLA-B region and hyper-sensitivity reactions to abacavir. Lancet 2002; 359: 1121-1122.
62. Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, Lai EH, Nangle K, Scott T, Spreen WR, Warren LL, Roses AD: Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004; 5: 203-211.
63. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M: Cost-effectiveness analysis of HLA B * 5701 genotyping in preventing aba-cavir hypersensitivity. Pharmacogenetics 2004; 14: 335-342.
64. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S: Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006; 43: 99-102.
65. Reeves I, Fisher M, Churchill D: Clinical utility of HLA-B*5701 testing in a UK clinic cohort. Abstract 667a; Presented at the 13th Conference on Retroviruses and Opportunistic Infections, Denver USA, February 2006.
66. Martin AM, Nolan D, Mallal S: HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing. Tissue Antigens 2005; 65: 571-574.
67. Martin AM, Krueger R, Almeida CA, Nolan D, Phillips E, Mallal S: A sensitive and rapid alternative to HLA typ-ing as a genetic screening test for aba-cavir hypersensitivity syndrome. Pharmacogenet Genomics 2006; 16: 353-357.
68. Moyle G: The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy. Drugs 2001; 61: 19-26.
69. Gangar M, Arias G, O'Brien JG, Kemper CA: Frequency of cutaneous reactions on rechallenge with nevirapine and delavirdine. Ann Pharmacother 2000; 34: 839-842.
70. Warren KJ, Boxwell DE, Kim NY, Drolet BA: Nevirapine-associated Stevens-Johnson syndrome. Lancet 1998; 351: 567.
71. Metry DW, Lahart CJ, Farmer KL, Hebert AA: Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine. J Am Acad Dermatol 2001; 44(suppl):354-357.
72. Barreiro P, Soriano V, Casas E, Estrada V, Tellez MJ, Hoetelmans R, de Requena DG, Jimenez Nacher I, Gonzalez Lahoz J: Prevention of nevirapine associated exanthema using slow dose escalation and/or corticosteroids. AIDS 2000; 14: 2153-2157.
73. De Luca A, Baracchini A, Baldini F, Zaccarelli M, Cingolani A, De Longis P, Di Giambenedetto S, Tozzi V, Rizzo MG, Murri R, Ippolito G, Ammassari A, Antinori A: Gender, use of corticosteroids and CD4 counts are predictive factors of nevirapine associated rash. AIDS 2000; 14:P182.
74. Max B, Sherer R: Management of the adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis 2000; 30(suppl 2):S96-S116.
75. Sanne I, Mommeja Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, Wakeford C, Shaw A, Quinn J, Gish RG, Rousseau F: Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005; 191: 825-829.
76. Benn PD, Mercey DE, Brink N, Scott G, Williams IG: Prophylaxis with a nevirapine containing triple regimen after exposure to HIV-1. Lancet 2001; 357: 687-688.
77. Centers for Disease Control and Prevention (CDC): Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures worldwide, 1997-2000. MMWR Morb Mortal Wkly Rep 2001; 49: 1153-1156.
78. Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, Keiser O, Biollaz J, Decosterd L, Telenti A: Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Ge-nomics 2005; 15: 1-5.
79. Almond LM, Boffito M, Hoggard PG, Bonora S, Raiteri R, Reynolds HE, Garazzino S, Sinicco A, Khoo SH, Back DJ, Di Perri G: The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS Res Hum Retroviruses 2004; 20: 716-722.
80. Nunez M, Gonzalez Requena D, Gonzalez Lahoz J, Soriano V: Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients. AIDS Res Hum Retroviruses 2003; 19: 187-188.
81. Haas DW, Bartlett JA, Andersen JW, Sanne I, Wilkinson GR, Hinkle J, Rousseau F, Ingram CD, Shaw A, Lederman MM, Kim RB: Pharmacogenetics of nevirapine associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis 2006; 43: 783-786.
82. Drummond NS, Vilar FJ, Naisbitt DJ, Hanson A, Woods A, Park BK, Pirmo-hamed M: Drug specific T cells in an HIV-positive patient with nevirapine induced hepatitis. Antivir Ther 2006; 11: 393-395.
83. Uetrecht J: Role of animal models in the study of drug-induced hypersensitivity reactions. Aaps J 2005; 7:E914-921.
84. Martin AM, Nolan D, James I, Cameron P, Keller J, Moore C, Phillips E, Christiansen FT, Mallal S: Predisposition to nevirapine hypersensitivity associated with HLA-DRB1 * 0101 and abrogated by low CD4 T-cell counts. AIDS 2005; 19: 97-99.
85. Littera R, Carcassi C, Masala A, Piano P, Serra P, Ortu F, Corso N, Casula B, La Nasa G, Contu L, Manconi PE: HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. Aids 2006; 20: 1621-1626.
86. Nunez M, Soriano V: Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Drug Saf 2005; 28: 53-66.